Tempus is a data analytics company that was founded by Eric Lefkofsky. The company has software and computers that can store, process and sift through large amounts of data to find patterns. Recently, Tempus has begun a partnership with the University of Chicago to help better treat cases of breast cancer.
Tempus’ capabilities include being able to do genomic sequencing for patients who are receiving treatment at the University of Chicago for breast cancer. In addition the company utilizes machine learning technology to build upon previous data from both past and existing patients. Genomic sequencing when combined with machine learning give cancer researchers and physicians a vast swathe of data that can better predict how a person will respond to a certain treatment option for cancer and how likely that treatment will be successful.
Doctors at the University of Chicago say that there is a large amount of information out there on cancer patients. They also say that there is lack of storage, analysis and sharing of data when it comes to past cancer patients. Tempus is changing this by storing data and allowing it to be shared and analyzed. The hope is that Tempus can help customize medicine and create an effective individually customized cancer solution for every patient that will be most effective for them.
Eric Lefkofsky is also the founder of Groupon. This is a popular online marketing company. Its business model involves working with businesses to offer customers large discounts or sales on products and services. In exchange for offering these large discounts or sales, the business or corporation is given access to a large customer base that is willing to try out the new product or service at the discounted value. Businesses get access to a large customer base, while customers get discounts and special offers through Groupon.
Mr. Lefkofsky also has an investment venture that is called Lightbank. This venture invests money in startups that have the potential to impact society or develop into big companies. Both Lightbank, Tempus and Groupon are based in the windy city of Chicago at 600 West Chicago Avenue along the banks of the Chicago River.
Eric Lefkofsky is the founder of Tempus, a cancer-fighting startup that aims to provide accurate data to the doctors serving at the University of Chicago so as to aid in treating breast cancer patients. Tempus, Chicago-based institution, has partnered with the University of Chicago Medicine so as to provide the University doctors and students with molecular sequencing and analysis to breast cancer specialists. This will help them create treatment plans regarding each person’s needs. The primary objective of Tempus is to provide data that lead to better results and permanent outcomes.
Eric Lefkofsky is an American Entrepreneur, co-founder and the Chief Executive Officer of the Tempus. Mr Eric has co-founded other organizations such as Groupon, where he is also a chairman, Echo Global Logistics, Mediaocean, Uptake, and the InnerWorkings. Eric Lefkofsky grew up and studied in Southfield, Michigan alongside his two siblings. He is the son of Bill and Sandy, an engineer and school teacher respectively. Eric has two siblings, one brother, and a sister, and they are all Jewish. Erick Paul attended Southfield-Lathrup High School and later joined the University of Michigan where he graduated with Honors.
Eric Lefkofsky has been an entrepreneur since he left college. His entrepreneurial journey started when he and his friend bought a company with capital borrowed from family and relatives. He later created an internet company that used to promote products online. He once served as the Chief Operating Officer of Halo till it got resolved in 2004. He created a logistics company, a media-technology company, which later turned to be a media Bank. He has served in these ventures as a co-founder and Chairman of the Board and the Chief Executive Officer for some. In 2016, he founded Tempus, which is expected to be of much help to the Chicago breast cancer patients. Click here to know more.
As a contributor in the world of science, you may be looking for a resource that will help you to gather the latest researched findings while providing you with an opportunity of making your own contributions. If that is the case, you may have landed on the right page as Oncotarget is one of the best tools that you could have in your list of resources for learning more about what is occurring in the world of science. The journal is peer reviewed and is published by Impact Journals.
It is highly recommended for scientific enthusiasts, researchers, and contributors to ensure that they’re navigating through resources that are valid and legitimate as they do not want to conduct their own researching based off of sources and findings that are false and/or inaccurate. Oncotarget is a legitimate site that uses scholarly reviewed articles in its posts and findings for users to learn from and use if needed and for whatever reason. They will not stoop down to any level in which they will post false information in pertinence to science just to simply receive more views. It is a good place for one to navigate to should they be making contributions in their own work or school assignments as the information that is uploaded on to the site are factual and adequately researched.
The website has been created with elements of simplicity so that one can easily navigate through a website that may have loads of complex information. If you’re not sure about what you can do to potentially make contributions to the world of science yourself, then you may be able to find the resources that may be necessary for you to do so. It is a great website that believes in progress and advancements as a human race. There seems to be no limits to what we can achieve and the only way for us to reach for it is by understanding and striving to progress in the field of science.
Follow Oncotarget on Twitter.
Seattle Genetics is a biotechnology company founded in 1998 by Clay Siegall. This company was established with the aim of coming up with a product pipeline that satisfied unmet medical needs. Seattle Genetics has since become an industry leader in the development of antibody- drug conjugates (ADCs), a technology that is designed to harness the power of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Dr. Clay Siegall, the founder, Chief Executive Officer, President and Chairman of the Board of Seattle Genetics brings a wealth of experience to this industry. He has a Ph.D. in Genetics from George Washington University. Previously, He worked at the National Cancer Institute and the National Health Institute between 1988 and 1991. He then went on to Bristol-Myers Squibb Pharmaceutical Research Institute, where he worked from 1991-1997. When Bristol-Myers decided to close its operations in Seattle, he went on to form Seattle Genetics based on the passion he had for making cancer treatment available and affordable to all.
It is during Dr. Siegall’s tenure at Seattle Genetics that the company has built a portfolio of antibody-based cancer therapies. The most well known of these is ADCETRIS (brentuximab vedotin), was granted approval by the United States Food and Drug Administration in 2001. This drug is currently available in 65 countries. Clay Siegall has also been instrumental in fundraising activities, having secured over $330 million through private and public financing. He has also secured strategic ADC collaborations with other companies like Genentech, Bayer, and Progenics among others, which have generated at least $65 million since 2001.
Dr. Clay Siegall’s dedication to the treatment and possible cure of cancer and other life-threatening illnesses using ADC therapy is a challenge to all of us. He has made this his life’s purpose. He has written over 70 publications and holds over 15 patents, all of which prove that he has a lot more in store for the medical world. Clay Siegall’s expertise in this field has led to his being invited to sit on the Boards of other companies, including Alder Biopharmaceuticals, Mirna Therapeutics, and Ultragenyx. Based on what he has achieved so far at Seattle Genetics, it is clear that Dr. Siegall is a man to watch in the field of genetics and ADC therapy.